Galunisertib + Placebo
Phase 2/3Completed 0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myelodysplastic Syndromes
Conditions
Myelodysplastic Syndromes
Trial Timeline
Mar 1, 2014 → Sep 1, 2017
NCT ID
NCT02008318About Galunisertib + Placebo
Galunisertib + Placebo is a phase 2/3 stage product being developed by Eli Lilly for Myelodysplastic Syndromes. The current trial status is completed. This product is registered under clinical trial identifier NCT02008318. Target conditions include Myelodysplastic Syndromes.
What happened to similar drugs?
7 of 19 similar drugs in Myelodysplastic Syndromes were approved
Approved (7) Terminated (7) Active (7)
Hype Score Breakdown
Clinical
15
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02008318 | Phase 2/3 | Completed |
Competing Products
20 competing products in Myelodysplastic Syndromes
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NEX-18a injection + Azacitidine Injection | Nanexa AB | Phase 1 | 23 |
| JSP191 | Jasper Therapeutics | Phase 1 | 11 |
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | Jasper Therapeutics | Phase 1 | 15 |
| GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II | GT Biopharma | Phase 1/2 | 14 |
| Erlotinib Hydrochloride | Astellas Pharma | Phase 2 | 35 |
| Decitabine + Decitabine + Decitabine | Eisai | Phase 2 | 35 |
| Decitabine + Valproic Acid | Eisai | Phase 2 | 35 |
| decitabine + decitabine | Eisai | Phase 2 | 35 |
| decitabine + azacitidine | Eisai | Approved | 35 |
| Decitabine | Eisai | Phase 2 | 27 |
| decitabine + decitabine + decitabine + decitabine | Eisai | Phase 1 | 29 |
| Decitabine, Arsenic Trioxide and Ascorbic Acid | Eisai | Phase 2 | 35 |
| Subcutaneous Decitabine | Eisai | Phase 1 | 21 |
| Decitabine | Eisai | Phase 2 | 35 |
| DSP-7888 | Sumitomo Pharma | Phase 1/2 | 32 |
| TP-0184 | Sumitomo Pharma | Phase 1/2 | 24 |
| Decitabine | Johnson & Johnson | Phase 2 | 35 |
| Epoetin alfa | Johnson & Johnson | Phase 2 | 27 |
| ZARNESTRA, tipifarnib, R115777 | Johnson & Johnson | Phase 2 | 35 |
| Decitabine | Johnson & Johnson | Phase 2 | 27 |